Condition

Systemic Juvenile Idiopathic Arthritis (SJIA) (1)

Overall Status

Completed (1)

Sign in for free

Phase

phase 3 (1)

Sponsor

Novartis Pharmaceuticals (1)

Collaborator

Intervention

acz885 150 mg (canakinumab) (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Industry (1)

Study Type

Interventional (1)

systemic juvenile idiopathic arthritis (sjia)

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Systemic Juvenile Idiopathic Arthritis (SJIA) Trial in Worldwide (ACZ885 150 mg (Canakinumab))

Completed

Systemic Juvenile Idiopathic Arthritis (SJIA)

ACZ885 150 mg (Canakinumab)

Los Angeles, California
+49 more

Jun 17, 2019